Methods for treating vasomotor symptoms in castrated...

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 31/573 (2006.01)

Patent

CA 2739887

The present invention is directed to methods of treating vasomotor symptoms in castrated prostatic cancer patients in need of treatment, comprising administering about 15 mg or less of cyproterone acetate per day to the patients. The present invention is further directed to dosage forms comprising about 1 mg to about 15 mg of cyproterone acetate and a package comprising a plurality of dosage forms comprising about 1 mg to about 15 mg of cyproterone acetate.

La présente invention concerne des procédés de traitement de symptômes vasomoteurs présentés par des patients castrés suite à un cancer de la prostate et nécessitant un traitement. Lesdits procédés comportent  l'administration d'environ 15 mg ou moins d'acétate de cyprotérone par jour aux patients. La présente invention concerne en outre des formes pharmaceutiques qui comportent environ 1 mg à environ 15 mg d'acétate de cyprotérone et un conditionnement qui comporte une pluralité de formes pharmaceutiques comportant environ 1 mg à environ 15 mg d'acétate de cyprotérone.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Methods for treating vasomotor symptoms in castrated... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods for treating vasomotor symptoms in castrated..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating vasomotor symptoms in castrated... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1637417

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.